Taken from long-acting opioid denominator in OpenPrescribing, with a calculated Oral Morphine Equivalence of <120mg a day of a long acting regular opioid.

From OpenPrescribing: "The calculations are based on likely doses of long acting, regular opioids, for example morphine sulphate tablets or fentanyl patches. For example, we have assumed that MST 60mg tablets are “high dose”, as they are usually taken as one tablet twice daily (120mg daily dose), whereas MST 30mg are not, as the daily dose…

This codelist contains codes for oestrogen and oestrogen-like drugs that potentially increase the risk of thrombotic events.

Drugs used as the denominator of the following [OpenPrescribing](https://openprescribing.net) measures:

* [Antibiotic stewardship: prescribing of trimethoprim vs nitrofurantoin](https://openprescribing.net/measure/trimethoprim/)

Drugs used as the numerator of the following [OpenPrescribing](https://openprescribing.net) measures:

* [Antibiotic stewardship: prescribing of trimethoprim vs nitrofurantoin](https://openprescribing.net/measure/trimethoprim/)

Antibacterial drugs contained with BNF section 5.1, as used by OpenPrescribing "Antibiotic stewardship: volume of antibiotic prescribing (KTT9)" measure.

List of "broad-spectrum" antibiotics used by the following OpenPrescribing measures based on [NICE guidance note KTT9](https://www.nice.org.uk/advice/ktt9):

* [Antibiotic stewardship: co-amoxiclav, cephalosporins & quinolones (KTT9)](https://openprescribing.net/measure/ktt9_cephalosporins/)
* [Antibiotic stewardship: co-amoxiclav, cephalosporins & quinolones (KTT9) prescribing volume](https://openprescribing.net/measure/ktt9_cephalosporins_star/)

All opioid-containing products which are given via buccal, nasal, or oromuscosal route of administration, EXCLUDING products listed in section 4.10 (substance misuse) of the legacy BNF code structure. Drugs outside of this, but not included in "opioid analgesics" in the BNF ARE included (e.g. co-codamol, alfentanil)

All opioid-containing products which are given via buccal, nasal, or oromuscosal route of administration, EXCLUDING products listed in section 4.10 (substance misuse) of the legacy BNF code structure. Drugs outside of this, but not included in "opioid analgesics" in the BNF ARE included (e.g. co-codamol, alfentanil)

All opioid-containing products which are given via inhaled route of administration, EXCLUDING products listed in section 4.10 (substance misuse) of the legacy BNF code structure. Drugs outside of this, but not included in "opioid analgesics" in the BNF ARE included (e.g. co-codamol, alfentanil)

All opioid-containing products which are given via inhaled route of administration, EXCLUDING products listed in section 4.10 (substance misuse) of the legacy BNF code structure. Drugs outside of this, but not included in "opioid analgesics" in the BNF ARE included (e.g. co-codamol, alfentanil)

All opioid-containing products which are given via oral route of administration, EXCLUDING products listed in section 4.10 (substance misuse) of the legacy BNF code structure. Drugs outside of this, but not included in "opioid analgesics" in the BNF ARE included (e.g. co-codamol, alfentanil)

All opioid-containing products which are given via oral route of administration, EXCLUDING products listed in section 4.10 (substance misuse) of the legacy BNF code structure. Drugs outside of this, but not included in "opioid analgesics" in the BNF ARE included (e.g. co-codamol, alfentanil)

All opioid-containing products which are given via parenteral route of administration, EXCLUDING products listed in section 4.10 (substance misuse) of the legacy BNF code structure. Drugs outside of this, but not included in "opioid analgesics" in the BNF ARE included (e.g. co-codamol, alfentanil)

All opioid-containing products which are given via parenteral route of administration, EXCLUDING products listed in section 4.10 (substance misuse) of the legacy BNF code structure. Drugs outside of this, but not included in "opioid analgesics" in the BNF ARE included (e.g. co-codamol, alfentanil)

All opioid-containing products which are given via rectal route of administration, EXCLUDING products listed in section 4.10 (substance misuse) of the legacy BNF code structure. Drugs outside of this, but not included in "opioid analgesics" in the BNF ARE included (e.g. co-codamol, alfentanil)